Some studies (51) have identified CXCL9 as a T cell chemokine related to the prognosis of head and neck cancer (51), prostate cancer (52), melanoma (53), ovarian cancer (54), gastric cancer (55) and other tumors, and studies primarily focus on the immune infiltration of CD8 T cells. Here, CD8A is linked to prostate cancer.